After Second Rejection, AMT Halts Glybera Development
BioWorld International Correspondent
Amsterdam Molecular Therapeutics (AMT) NV's bid to become the first Western biotechnology firm to gain a gene therapy approval suffered a second rebuff, as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) stood over its original negative opinion on a marketing authorization application for Glybera (alipogene tiparvovec), which is in development for the ultra-rare indication lipoprotein lipase deficiency.
Shares in the company (AMSTERDAM:AMT) plunged 51 percent when the news was disclosed Friday, to close at €0.38 (US$0.43).
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter